Dear Colleagues,

Ample is the literature evidence that pinpoints neurodegenerative disorders as one of the greatest threats to public health. On the other hand, respiratory diseases also affect humanity, globally, with lung cancer and chronic lung diseases being responsible for extensive morbidity and mortality. Despite both being life-threatening diseases, affected patients often experience significant delay before a definitive diagnosis if symptoms are mild or overlap with other disorders. It follows that an accurate and early diagnosis of pathology would be of crucial importance for these individuals. Recent advances in genomics, proteomics, and metabolomics have generated many candidate biomarkers with clinical value. Being potentially useful, along the whole spectrum of the disease process, biomarkers have gained immense scientific interest as they can be helpful in improving patient outcomes and survival rates. However, despite an explosion of potential biomarkers in diagnosis, prediction, and prognosis, due to the lack of a validation process, only a few of them have made the transition into clinical practice.

The aim of this Special Issue is to attract contributions in the field of neurodegenerative and respiratory pathologies with a special emphasis on the discovery and validation of biomarkers that could be useful for their diagnosis.

Prof. Dr. Paolo Iadarola
Dr. Simona Viglio
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. High-Throughput is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• biomarkers
• pulmonary disorders
• neurodegenerative disorders